Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6052 recombinant zoster vaccine Phase I/II trial in adults aged 40 years and older
CTR20263963Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SYS6052 in herpes zoster (HZ) (4 arms), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Solicited adverse events, Unsolicited adverse events and 4 more. Started Oct 2026; status: active.
02
Drugs
SYS6052
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on CTR20263963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263963.